Company intelligence / Profile preview

Immunocine

Cancún, Quintana Roo, Mexicoimmunocine.com ↗

Ownership: Private
Development stage: Commercial

Overview

Immunocine’s IDCT protocol has shown significant success in refractory or incurable cancers at their center, with reported cases of tumor regression and improved patient outcomes. The approach has been studied extensively since its discovery in 2006, supported by peer-reviewed science and ongoing clinical research at Texas Medical Center/Baylor College of Medicine/Diakonos Oncology. However, published peer-reviewed clinical trial data from Immunocine itself are not cited.

Therapeutic areas: Oncology
Modalities: Dendritic cell-based immunotherapy (autologous dendritic cells loaded with mRNA and proteins)
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

IDCT

Commercial

Indications: Solid tumors

Partnerships

Galenia Hospital (Cancún) – site of treatment administration; partnership for medical care deliveryCollaboration/connection with Diakonos Oncology on R&D and clinical development

Beyond the preview

Go deeper on Immunocine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunocine.